First major trial aims to stop deadly clots in hospitalized teens
NCT ID NCT06628778
Summary
This study aims to find out if a blood-thinning medication (dalteparin) can safely prevent dangerous blood clots in critically ill teenagers during their hospital stay. It will enroll 802 teens aged 12-18 who are in intensive care and identified as high-risk for clots. The trial compares the medication against the current standard of care, which is no preventive blood thinner.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM (VTE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins All Children"s Hospital
St. Petersburg, Florida, 33704, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.